TGM7

Across TCGA pan-cancer cohorts, TGM7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TGM7 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TGM7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGM7 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

LUAD, KICH, and LIHC are the cancer types where TGM7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.057	0.680	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LIHC	DFS	Median	All	0.081	0.555	<.001	12	view →
READ	DFS	Median	III,IV	0.255	0.757	.008	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	OS	Median	All	0.222	0.680	.031	6	view →
LUSC	DFS	Median	All	1.000	0.383	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TGM7–LUAD (OS)

Open the LUAD breakdown →